SavedAdd your journal

Journals / Türk Hijyen ve Deneysel Biyoloji Dergisi / 1999 / Cilt: 56 - Sayı: 1

The value of serum HBV DNA measurements in monitoring therapy with interferon alpha in patients with chronic active hepatitis B virus infection

Kronik aktif hepatit B virüs infeksiyonlu olgularda alfa interferon tedavisinin izlenmesinde serumda hepatit B virüs DNA ölçümlerinin değeri

C. Murat BEKER
Ufuk DİZER
Levent HAYAT
Volkan ÖZGÜVEN
Ali İNAL
Mesut ORTATATLI
Pages
5–11
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The proportion of the disappearance of HBV DNA was determined as 33.3% in TG and 10.0 % in CG (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In this study, serum hepatitis B viral DNA (HBV DNA) levels were measured by molecular hybridization (MH) for detecting the response to interferon alpha (α-IFN) therapy in patients with chronic active hepatitis B virus infection.
📊
Key Findings & Data:HBV DNA positive six and negative nine cases for the therapy group (TG) and 20 untreated cases for the control group (CG) were investigated.
💡
Conclusion & Impact:The proportion of the disappearance of HBV DNA was determined as 33.3% in TG and 10.0 % in CG (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

In this study, serum hepatitis B viral DNA (HBV DNA) levels were measured by molecular hybridization (MH) for detecting the response to interferon alpha (α-IFN) therapy in patients with chronic active hepatitis B virus infection. HBV DNA positive six and negative nine cases for the therapy group (TG) and 20 untreated cases for the control group (CG) were investigated. TG was treated with 4.5 million unit (MU) α -IFN (three times weekly) for six months and followed up during 12 months. The proportion of the disappearance of HBV DNA was determined as 33.3% in TG and 10.0 % in CG (p

Özet

Çalışmamızda, moleküler hibridizasyon (MH) yöntemi ile serum Hepatitis B Viral DNA (HBV DNA) düzeyleri ölçülerek, kronik aktif hepatit B virüs infeksiyonluların alfa-interferon (α-IFN) tedavisine yanıtı araştırılmıştır. HBV DNA pozitif altı, negatif dokuz olgu tedavi grubu (TG); α-IFN ile tedaviyi kabul etmeyen 20 olgu da kontrol grubu (KG) olarak alınmıştır. TG'na altı ay, haftada üç kez, 4.5 milyon ünite (MU) α-IFN uygulanmıştır, olgular 12 ay süre ile izlenmiştir. HBV DNA negatifleşme oranı TG'da %33,3, KG'da %10 olarak bulunmuştur (p

🔖

Cite This Article

BEKER, C. M., DİZER, U., HAYAT, L., ÖZGÜVEN, V., İNAL, A., ORTATATLI, M. (2022). The value of serum HBV DNA measurements in monitoring therapy with interferon alpha in patients with chronic active hepatitis B virus infection. Türk Hijyen ve Deneysel Biyoloji Dergisi, Cilt: 56 - Sayı: 1, 5–11. https://ajindex.com/articles/625294

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Wong VC, IP HM, Reesink HV. Prevention of the HBsAg carrier state ın newborn ıntants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis B vaccine and hepatıtıs B immunglobulin. Lancet 1984; t:92 t-926. 2-Robinson WS. Hepatitis B virus and hepatltis D vırus. In: Mandeli GL, Bennet JE, Dolin R.eds. Principles and Practice of Infectious Diseases,fourth ed. New York: Churchill Livingstone,t995: t4061439. 3-lkeda T, lever AMl, Thomas HC. Evidenee for a deficiency of interferon production ın patients with chronic HBV infection acquired in adult life. Hepatology t986;6:962. 4-Bonino F, Brunetto MR. Hepatitis B virus heterogenity, one of many factors influencing the severity of hepatitis. Br J Hepatol t993; t8:5. 5-Harrison T J. HBV DNA in peripheral blood leukocytes. A brief revıew. J Med Virol t 990: 3 t:33. 6-Wong OKU, Cheung AM. O'rourke K, et al. Effects of a·IFN treatment in patients with HBeAg positive chronic hepatitis B; a meta analysis. Ann Intern Med t996:t19:3t2-323. 7-Alexander GJM, Brahm J, Fagan EA. loss ot HBsAg with interferon therapy ın chronic hepatıtis B virus infection. Laneet t 987; ii:66-68. 8-Neurath AR, Jameson BA, Huima T. Hepatitis B virus proteins eliciting protective immunity. Microbiol Sci t987;4:45. 9-Perri llo RP, Regenstein FG, Peters MG. Prednisone with drawal followed by recombinant alpha inteneron in the treatment of chronic type B hepatitis: A randomized, controlled trial. Ann Intern Med t99 t: t t4:629-634. 10-Ruiz-Moreno M, Rua MJ, Molina J. Prospective, randomized controlled trial of inteneron alpha in children with ehronic hepatitis. Br Hepatol t99t; t3: t035-t039. 11-Williams SJ, Saird-Lambert JA, Farrelı GC. Inhibition ot theophylline metabolism by inteneron. Lancet t987; 2:939-94 t. 12-Brunetto MS, OIiveri F, Colombatto P. Treatment ot ehronic anti -HBe positi'le hepatitis B with ıFN-u. J Hepatol t995: 22 (Suppı): 42-44. 13-Theilmann L, Salteld J, Kommerell B, PtaH E. Detection ot antibadies to proteins encoded by the X region of hepatitis B virus in sera ot patients with chronie hepatitis B virus infection: Correiation with other hepatitis B virus markers. Hepatogastroenterol t 988;3:35. 14-Perez V, Findor J, Tanno H, Sorda J. A controlled trial of high-dose inteneron, alone and tollowing prednisone pithdrawal, in the treatment ot chronic hepatitis B: long-term toııow up. Gut t992; 8 (suppl):32.